Beaconlight Capital LLC Raises Position in Natera, Inc. $NTRA

Beaconlight Capital LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 44.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,589 shares of the medical research company’s stock after buying an additional 10,303 shares during the quarter. Natera accounts for about 3.6% of Beaconlight Capital LLC’s holdings, making the stock its 9th biggest holding. Beaconlight Capital LLC’s holdings in Natera were worth $6,717,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Integrated Wealth Concepts LLC increased its position in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the 2nd quarter valued at $558,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total value of $818,700.00. Following the transaction, the insider directly owned 134,643 shares in the company, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 over the last ninety days. Insiders own 5.05% of the company’s stock.

Natera Trading Down 1.0%

Shares of NTRA stock opened at $261.99 on Friday. The firm has a fifty day simple moving average of $240.75 and a two-hundred day simple moving average of $221.61. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. The firm has a market capitalization of $37.52 billion, a PE ratio of -160.73 and a beta of 1.51.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Guggenheim raised their price objective on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, July 15th. Morgan Stanley lifted their price target on Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Finally, UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.